Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.
Identifieur interne : 000023 ( Main/Exploration ); précédent : 000022; suivant : 000024Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.
Auteurs : Mark G. Thompson [Géorgie (pays)] ; Jeffrey C. Kwong [Canada] ; Annette K. Regan [Australie] ; Mark A. Katz [Israël] ; Steven J. Drews [Canada] ; Eduardo Azziz-Baumgartner [Géorgie (pays)] ; Nicola P. Klein ; Hannah Chung ; Paul V. Effler [Australie] ; Becca S. Feldman ; Kimberley Simmonds [Canada] ; Brandy E. Wyant [États-Unis] ; Fatimah S. Dawood [Géorgie (pays)] ; Michael L. Jackson [États-Unis] ; Deshayne B. Fell [Canada] ; Avram Levy [Australie] ; Noam Barda ; Lawrence W. Svenson [Canada] ; Rebecca V. Fink [États-Unis] ; Sarah W. Ball [États-Unis] ; Allison Naleway [États-Unis]Source :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2019.
Descripteurs français
- KwdFr :
- ARN viral (génétique), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Australie (épidémiologie), Canada (épidémiologie), Efficacité du vaccin (MeSH), Femelle (MeSH), Grippe humaine (diagnostic), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Grossesse (MeSH), Hospitalisation (statistiques et données numériques), Humains (MeSH), Immunogénicité des vaccins (MeSH), Plan de recherche (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sous-type H1N1 du virus de la grippe A (pathogénicité), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (isolement et purification), Sous-type H3N2 du virus de la grippe A (pathogénicité), Vaccination (statistiques et données numériques), Vaccins antigrippaux (administration et posologie), Virus influenza B (génétique), Virus influenza B (isolement et purification), Virus influenza B (pathogénicité), États-Unis (épidémiologie), Études rétrospectives (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- diagnostic : Grippe humaine.
- génétique : ARN viral, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- immunologie : Grippe humaine.
- isolement et purification : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- pathogénicité : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Hospitalisation, Vaccination.
- épidémiologie : Australie, Canada, Grippe humaine, États-Unis.
- Adolescent, Adulte, Adulte d'âge moyen, Efficacité du vaccin, Femelle, Grossesse, Humains, Immunogénicité des vaccins, Plan de recherche, Saisons, Études rétrospectives.
- Wicri :
- geographic : Australie, Canada, États-Unis.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Australia (epidemiology), Canada (epidemiology), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Immunogenicity, Vaccine (MeSH), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza A Virus, H1N1 Subtype (pathogenicity), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza A Virus, H3N2 Subtype (pathogenicity), Influenza B virus (genetics), Influenza B virus (isolation & purification), Influenza B virus (pathogenicity), Influenza Vaccines (administration & dosage), Influenza, Human (diagnosis), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Middle Aged (MeSH), Pregnancy (MeSH), RNA, Viral (genetics), Research Design (MeSH), Retrospective Studies (MeSH), Seasons (MeSH), United States (epidemiology), Vaccination (statistics & numerical data), Vaccine Potency (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Australia, Canada, United States.
- diagnosis : Influenza, Human.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, RNA, Viral.
- immunology : Influenza, Human.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- pathogenicity : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- prevention & control : Influenza, Human.
- statistics & numerical data : Hospitalization, Vaccination.
- Adolescent, Adult, Female, Humans, Immunogenicity, Vaccine, Middle Aged, Pregnancy, Research Design, Retrospective Studies, Seasons, Vaccine Potency.
Abstract
BACKGROUND
To date, no study has examined influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza-associated hospitalizations during pregnancy.
METHODS
The Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) consisted of public health or healthcare systems with integrated laboratory, medical, and vaccination records in Australia, Canada (Alberta and Ontario), Israel, and the United States (California, Oregon, and Washington). Sites identified pregnant women aged 18 through 50 years whose pregnancies overlapped with local influenza seasons from 2010 through 2016. Administrative data were used to identify hospitalizations with acute respiratory or febrile illness (ARFI) and clinician-ordered real-time reverse transcription polymerase chain reaction (rRT-PCR) testing for influenza viruses. Overall IVE was estimated using the test-negative design and adjusting for site, season, season timing, and high-risk medical conditions.
RESULTS
Among 19450 hospitalizations with an ARFI discharge diagnosis (across 25 site-specific study seasons), only 1030 (6%) of the pregnant women were tested for influenza viruses by rRT-PCR. Approximately half of these women had pneumonia or influenza discharge diagnoses (54%). Influenza A or B virus infections were detected in 598/1030 (58%) of the ARFI hospitalizations with influenza testing. Across sites and seasons, 13% of rRT-PCR-confirmed influenza-positive pregnant women were vaccinated compared with 22% of influenza-negative pregnant women; the adjusted overall IVE was 40% (95% confidence interval = 12%-59%) against influenza-associated hospitalization during pregnancy.
CONCLUSION
Between 2010 and 2016, influenza vaccines offered moderate protection against laboratory-confirmed influenza-associated hospitalizations during pregnancy, which may further inform the benefits of maternal influenza vaccination programs.
DOI: 10.1093/cid/ciy737
PubMed: 30307490
Affiliations:
- Australie, Canada, Géorgie (pays), Israël, États-Unis
- Alberta, Massachusetts, Ontario, Oregon, Washington (État)
- Calgary, Edmonton, Ottawa, Toronto
- Université de Calgary, Université de Toronto
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.</title><author><name sortKey="Thompson, Mark G" sort="Thompson, Mark G" uniqKey="Thompson M" first="Mark G" last="Thompson">Mark G. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Public Health Ontario.</nlm:affiliation><wicri:noCountry code="no comma">Public Health Ontario.</wicri:noCountry></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Family and Community Medicine, University of Toronto.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Dalla Lana School of Public Health, University of Toronto.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>University Health Network, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Regan, Annette K" sort="Regan, Annette K" uniqKey="Regan A" first="Annette K" last="Regan">Annette K. Regan</name><affiliation><nlm:affiliation>School of Public Health, Curtin University, Perth.</nlm:affiliation><wicri:noCountry code="subField">Perth</wicri:noCountry></affiliation><affiliation wicri:level="1"><nlm:affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Katz, Mark A" sort="Katz, Mark A" uniqKey="Katz M" first="Mark A" last="Katz">Mark A. Katz</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Medical School for International Health, Ben Gurion University, Bersheva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>School of Public Health, Medical School for International Health, Ben Gurion University, Bersheva</wicri:regionArea><wicri:noRegion>Bersheva</wicri:noRegion></affiliation><affiliation><nlm:affiliation>University of Michigan School of Public Health, Ann Arbor.</nlm:affiliation><wicri:noCountry code="subField">Ann Arbor</wicri:noCountry></affiliation></author><author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name><affiliation><nlm:affiliation>University of Alberta.</nlm:affiliation><wicri:noCountry code="no comma">University of Alberta.</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>ProvLab Alberta, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ProvLab Alberta, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Azziz Baumgartner, Eduardo" sort="Azziz Baumgartner, Eduardo" uniqKey="Azziz Baumgartner E" first="Eduardo" last="Azziz-Baumgartner">Eduardo Azziz-Baumgartner</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name><affiliation><nlm:affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland.</nlm:affiliation><wicri:noCountry code="subField">Oakland</wicri:noCountry></affiliation></author><author><name sortKey="Chung, Hannah" sort="Chung, Hannah" uniqKey="Chung H" first="Hannah" last="Chung">Hannah Chung</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation></author><author><name sortKey="Effler, Paul V" sort="Effler, Paul V" uniqKey="Effler P" first="Paul V" last="Effler">Paul V. Effler</name><affiliation wicri:level="1"><nlm:affiliation>Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Communicable Disease Control Directorate, Department of Health Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Feldman, Becca S" sort="Feldman, Becca S" uniqKey="Feldman B" first="Becca S" last="Feldman">Becca S. Feldman</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Simmonds, Kimberley" sort="Simmonds, Kimberley" uniqKey="Simmonds K" first="Kimberley" last="Simmonds">Kimberley Simmonds</name><affiliation wicri:level="4"><nlm:affiliation>Cumming School of Medicine, University of Calgary.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Alberta Health, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Wyant, Brandy E" sort="Wyant, Brandy E" uniqKey="Wyant B" first="Brandy E" last="Wyant">Brandy E. Wyant</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Dawood, Fatimah S" sort="Dawood, Fatimah S" uniqKey="Dawood F" first="Fatimah S" last="Dawood">Fatimah S. Dawood</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Michael L" sort="Jackson, Michael L" uniqKey="Jackson M" first="Michael L" last="Jackson">Michael L. Jackson</name><affiliation wicri:level="2"><nlm:affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Kaiser Permanente Washington Health Research Institute, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Fell, Deshayne B" sort="Fell, Deshayne B" uniqKey="Fell D" first="Deshayne B" last="Fell">Deshayne B. Fell</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>School of Epidemiology and Public Health, University of Ottawa.</nlm:affiliation><wicri:noCountry code="subField">University of Ottawa</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Ottawa</wicri:regionArea><placeName><settlement type="city">Ottawa</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Levy, Avram" sort="Levy, Avram" uniqKey="Levy A" first="Avram" last="Levy">Avram Levy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine, Nedlands, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Barda, Noam" sort="Barda, Noam" uniqKey="Barda N" first="Noam" last="Barda">Noam Barda</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Svenson, Lawrence W" sort="Svenson, Lawrence W" uniqKey="Svenson L" first="Lawrence W" last="Svenson">Lawrence W. Svenson</name><affiliation wicri:level="3"><nlm:affiliation>Alberta Health, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation><affiliation><nlm:affiliation>Division of Preventive Medicine.</nlm:affiliation><wicri:noCountry code="no comma">Division of Preventive Medicine.</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>School of Public Health, University of Alberta, Edmonton.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName><wicri:orgArea>School of Public Health, University of Alberta</wicri:orgArea></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Community Health Sciences, University of Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Community Health Sciences, University of Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Fink, Rebecca V" sort="Fink, Rebecca V" uniqKey="Fink R" first="Rebecca V" last="Fink">Rebecca V. Fink</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Sarah W" sort="Ball, Sarah W" uniqKey="Ball S" first="Sarah W" last="Ball">Sarah W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Naleway, Allison" sort="Naleway, Allison" uniqKey="Naleway A" first="Allison" last="Naleway">Allison Naleway</name><affiliation wicri:level="2"><nlm:affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Center for Health Research, Kaiser Permanente Northwest, Portland</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30307490</idno><idno type="pmid">30307490</idno><idno type="doi">10.1093/cid/ciy737</idno><idno type="wicri:Area/Main/Corpus">000041</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000041</idno><idno type="wicri:Area/Main/Curation">000041</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000041</idno><idno type="wicri:Area/Main/Exploration">000041</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.</title><author><name sortKey="Thompson, Mark G" sort="Thompson, Mark G" uniqKey="Thompson M" first="Mark G" last="Thompson">Mark G. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Public Health Ontario.</nlm:affiliation><wicri:noCountry code="no comma">Public Health Ontario.</wicri:noCountry></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Family and Community Medicine, University of Toronto.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Dalla Lana School of Public Health, University of Toronto.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>University Health Network, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Regan, Annette K" sort="Regan, Annette K" uniqKey="Regan A" first="Annette K" last="Regan">Annette K. Regan</name><affiliation><nlm:affiliation>School of Public Health, Curtin University, Perth.</nlm:affiliation><wicri:noCountry code="subField">Perth</wicri:noCountry></affiliation><affiliation wicri:level="1"><nlm:affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Katz, Mark A" sort="Katz, Mark A" uniqKey="Katz M" first="Mark A" last="Katz">Mark A. Katz</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Medical School for International Health, Ben Gurion University, Bersheva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>School of Public Health, Medical School for International Health, Ben Gurion University, Bersheva</wicri:regionArea><wicri:noRegion>Bersheva</wicri:noRegion></affiliation><affiliation><nlm:affiliation>University of Michigan School of Public Health, Ann Arbor.</nlm:affiliation><wicri:noCountry code="subField">Ann Arbor</wicri:noCountry></affiliation></author><author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name><affiliation><nlm:affiliation>University of Alberta.</nlm:affiliation><wicri:noCountry code="no comma">University of Alberta.</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>ProvLab Alberta, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ProvLab Alberta, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Azziz Baumgartner, Eduardo" sort="Azziz Baumgartner, Eduardo" uniqKey="Azziz Baumgartner E" first="Eduardo" last="Azziz-Baumgartner">Eduardo Azziz-Baumgartner</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name><affiliation><nlm:affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland.</nlm:affiliation><wicri:noCountry code="subField">Oakland</wicri:noCountry></affiliation></author><author><name sortKey="Chung, Hannah" sort="Chung, Hannah" uniqKey="Chung H" first="Hannah" last="Chung">Hannah Chung</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation></author><author><name sortKey="Effler, Paul V" sort="Effler, Paul V" uniqKey="Effler P" first="Paul V" last="Effler">Paul V. Effler</name><affiliation wicri:level="1"><nlm:affiliation>Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Communicable Disease Control Directorate, Department of Health Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Feldman, Becca S" sort="Feldman, Becca S" uniqKey="Feldman B" first="Becca S" last="Feldman">Becca S. Feldman</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Simmonds, Kimberley" sort="Simmonds, Kimberley" uniqKey="Simmonds K" first="Kimberley" last="Simmonds">Kimberley Simmonds</name><affiliation wicri:level="4"><nlm:affiliation>Cumming School of Medicine, University of Calgary.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Alberta Health, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Wyant, Brandy E" sort="Wyant, Brandy E" uniqKey="Wyant B" first="Brandy E" last="Wyant">Brandy E. Wyant</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Dawood, Fatimah S" sort="Dawood, Fatimah S" uniqKey="Dawood F" first="Fatimah S" last="Dawood">Fatimah S. Dawood</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Michael L" sort="Jackson, Michael L" uniqKey="Jackson M" first="Michael L" last="Jackson">Michael L. Jackson</name><affiliation wicri:level="2"><nlm:affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Kaiser Permanente Washington Health Research Institute, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Fell, Deshayne B" sort="Fell, Deshayne B" uniqKey="Fell D" first="Deshayne B" last="Fell">Deshayne B. Fell</name><affiliation><nlm:affiliation>Institute for Clinical Evaluative Sciences.</nlm:affiliation><wicri:noCountry code="no comma">Institute for Clinical Evaluative Sciences.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>School of Epidemiology and Public Health, University of Ottawa.</nlm:affiliation><wicri:noCountry code="subField">University of Ottawa</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Children's Hospital of Eastern Ontario Research Institute, Ottawa</wicri:regionArea><placeName><settlement type="city">Ottawa</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Levy, Avram" sort="Levy, Avram" uniqKey="Levy A" first="Avram" last="Levy">Avram Levy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine, Nedlands, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Barda, Noam" sort="Barda, Noam" uniqKey="Barda N" first="Noam" last="Barda">Noam Barda</name><affiliation><nlm:affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</nlm:affiliation><wicri:noCountry code="subField">Tel Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Svenson, Lawrence W" sort="Svenson, Lawrence W" uniqKey="Svenson L" first="Lawrence W" last="Svenson">Lawrence W. Svenson</name><affiliation wicri:level="3"><nlm:affiliation>Alberta Health, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health, Edmonton</wicri:regionArea><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName></affiliation><affiliation><nlm:affiliation>Division of Preventive Medicine.</nlm:affiliation><wicri:noCountry code="no comma">Division of Preventive Medicine.</wicri:noCountry></affiliation><affiliation wicri:level="3"><nlm:affiliation>School of Public Health, University of Alberta, Edmonton.</nlm:affiliation><country>Canada</country><placeName><settlement type="city">Edmonton</settlement><region type="state">Alberta</region></placeName><wicri:orgArea>School of Public Health, University of Alberta</wicri:orgArea></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Community Health Sciences, University of Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Community Health Sciences, University of Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Fink, Rebecca V" sort="Fink, Rebecca V" uniqKey="Fink R" first="Rebecca V" last="Fink">Rebecca V. Fink</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Sarah W" sort="Ball, Sarah W" uniqKey="Ball S" first="Sarah W" last="Ball">Sarah W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>Abt Associates, Cambridge, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Abt Associates, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Naleway, Allison" sort="Naleway, Allison" uniqKey="Naleway A" first="Allison" last="Naleway">Allison Naleway</name><affiliation wicri:level="2"><nlm:affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Center for Health Research, Kaiser Permanente Northwest, Portland</wicri:cityArea></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Australia (epidemiology)</term><term>Canada (epidemiology)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Immunogenicity, Vaccine (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza A Virus, H1N1 Subtype (pathogenicity)</term><term>Influenza A Virus, H3N2 Subtype (genetics)</term><term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term><term>Influenza A Virus, H3N2 Subtype (pathogenicity)</term><term>Influenza B virus (genetics)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza B virus (pathogenicity)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (diagnosis)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Middle Aged (MeSH)</term><term>Pregnancy (MeSH)</term><term>RNA, Viral (genetics)</term><term>Research Design (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Seasons (MeSH)</term><term>United States (epidemiology)</term><term>Vaccination (statistics & numerical data)</term><term>Vaccine Potency (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (génétique)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Australie (épidémiologie)</term><term>Canada (épidémiologie)</term><term>Efficacité du vaccin (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (diagnostic)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Grossesse (MeSH)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Immunogénicité des vaccins (MeSH)</term><term>Plan de recherche (MeSH)</term><term>Saisons (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (génétique)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Sous-type H1N1 du virus de la grippe A (pathogénicité)</term><term>Sous-type H3N2 du virus de la grippe A (génétique)</term><term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term><term>Sous-type H3N2 du virus de la grippe A (pathogénicité)</term><term>Vaccination (statistiques et données numériques)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Virus influenza B (génétique)</term><term>Virus influenza B (isolement et purification)</term><term>Virus influenza B (pathogénicité)</term><term>États-Unis (épidémiologie)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Australia</term><term>Canada</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Australie</term><term>Canada</term><term>Grippe humaine</term><term>États-Unis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Female</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Middle Aged</term><term>Pregnancy</term><term>Research Design</term><term>Retrospective Studies</term><term>Seasons</term><term>Vaccine Potency</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Efficacité du vaccin</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Plan de recherche</term><term>Saisons</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term><term>Canada</term><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>To date, no study has examined influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza-associated hospitalizations during pregnancy.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) consisted of public health or healthcare systems with integrated laboratory, medical, and vaccination records in Australia, Canada (Alberta and Ontario), Israel, and the United States (California, Oregon, and Washington). Sites identified pregnant women aged 18 through 50 years whose pregnancies overlapped with local influenza seasons from 2010 through 2016. Administrative data were used to identify hospitalizations with acute respiratory or febrile illness (ARFI) and clinician-ordered real-time reverse transcription polymerase chain reaction (rRT-PCR) testing for influenza viruses. Overall IVE was estimated using the test-negative design and adjusting for site, season, season timing, and high-risk medical conditions.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Among 19450 hospitalizations with an ARFI discharge diagnosis (across 25 site-specific study seasons), only 1030 (6%) of the pregnant women were tested for influenza viruses by rRT-PCR. Approximately half of these women had pneumonia or influenza discharge diagnoses (54%). Influenza A or B virus infections were detected in 598/1030 (58%) of the ARFI hospitalizations with influenza testing. Across sites and seasons, 13% of rRT-PCR-confirmed influenza-positive pregnant women were vaccinated compared with 22% of influenza-negative pregnant women; the adjusted overall IVE was 40% (95% confidence interval = 12%-59%) against influenza-associated hospitalization during pregnancy.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Between 2010 and 2016, influenza vaccines offered moderate protection against laboratory-confirmed influenza-associated hospitalizations during pregnancy, which may further inform the benefits of maternal influenza vaccination programs.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30307490</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>04</Month><Day>24</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.</ArticleTitle><Pagination><MedlinePgn>1444-1453</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciy737</ELocationID><Abstract><AbstractText Label="BACKGROUND">To date, no study has examined influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza-associated hospitalizations during pregnancy.</AbstractText><AbstractText Label="METHODS">The Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) consisted of public health or healthcare systems with integrated laboratory, medical, and vaccination records in Australia, Canada (Alberta and Ontario), Israel, and the United States (California, Oregon, and Washington). Sites identified pregnant women aged 18 through 50 years whose pregnancies overlapped with local influenza seasons from 2010 through 2016. Administrative data were used to identify hospitalizations with acute respiratory or febrile illness (ARFI) and clinician-ordered real-time reverse transcription polymerase chain reaction (rRT-PCR) testing for influenza viruses. Overall IVE was estimated using the test-negative design and adjusting for site, season, season timing, and high-risk medical conditions.</AbstractText><AbstractText Label="RESULTS">Among 19450 hospitalizations with an ARFI discharge diagnosis (across 25 site-specific study seasons), only 1030 (6%) of the pregnant women were tested for influenza viruses by rRT-PCR. Approximately half of these women had pneumonia or influenza discharge diagnoses (54%). Influenza A or B virus infections were detected in 598/1030 (58%) of the ARFI hospitalizations with influenza testing. Across sites and seasons, 13% of rRT-PCR-confirmed influenza-positive pregnant women were vaccinated compared with 22% of influenza-negative pregnant women; the adjusted overall IVE was 40% (95% confidence interval = 12%-59%) against influenza-associated hospitalization during pregnancy.</AbstractText><AbstractText Label="CONCLUSION">Between 2010 and 2016, influenza vaccines offered moderate protection against laboratory-confirmed influenza-associated hospitalizations during pregnancy, which may further inform the benefits of maternal influenza vaccination programs.</AbstractText><CopyrightInformation>Published by Oxford University Press for the Infectious Diseases Society of America 2018.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Mark G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Ontario.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family and Community Medicine, University of Toronto.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regan</LastName><ForeName>Annette K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>School of Public Health, Curtin University, Perth.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Medical School for International Health, Ben Gurion University, Bersheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Michigan School of Public Health, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drews</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>University of Alberta.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ProvLab Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azziz-Baumgartner</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Effler</LastName><ForeName>Paul V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Becca S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmonds</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cumming School of Medicine, University of Calgary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Health, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyant</LastName><ForeName>Brandy E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Abt Associates, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawood</LastName><ForeName>Fatimah S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fell</LastName><ForeName>Deshayne B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Avram</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barda</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenson</LastName><ForeName>Lawrence W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Alberta Health, Edmonton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Preventive Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Alberta, Edmonton.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health Sciences, University of Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Rebecca V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Abt Associates, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Abt Associates, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PREVENT Workgroup</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2019 Apr 24;68(9):1454-1455</RefSource><PMID Version="1">30307481</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2019 Aug 30;69(6):1085-1086</RefSource><PMID Version="1">30753401</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2019 Aug 30;69(6):1084-1085</RefSource><PMID Version="1">30753442</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064166" MajorTopicYN="Y">Vaccine Potency</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">hospitalization</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">pregnancy</Keyword><Keyword MajorTopicYN="Y">pregnant women</Keyword><Keyword MajorTopicYN="Y">vaccine effectiveness</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Shikha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shifflet</LastName><ForeName>Pat</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchan</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booth</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russel</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riesel</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glatman-Freedman</LastName><ForeName>Aharona</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandelboim</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leventer-Roberts</LastName><ForeName>Maya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irving</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crane</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>Ned</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goddard</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modaressi</LastName><ForeName>Sharareh</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30307490</ArticleId><ArticleId IdType="pii">5126390</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy737</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>Géorgie (pays)</li><li>Israël</li><li>États-Unis</li></country><region><li>Alberta</li><li>Massachusetts</li><li>Ontario</li><li>Oregon</li><li>Washington (État)</li></region><settlement><li>Calgary</li><li>Edmonton</li><li>Ottawa</li><li>Toronto</li></settlement><orgName><li>Université de Calgary</li><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Barda, Noam" sort="Barda, Noam" uniqKey="Barda N" first="Noam" last="Barda">Noam Barda</name><name sortKey="Chung, Hannah" sort="Chung, Hannah" uniqKey="Chung H" first="Hannah" last="Chung">Hannah Chung</name><name sortKey="Feldman, Becca S" sort="Feldman, Becca S" uniqKey="Feldman B" first="Becca S" last="Feldman">Becca S. Feldman</name><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name></noCountry><country name="Géorgie (pays)"><noRegion><name sortKey="Thompson, Mark G" sort="Thompson, Mark G" uniqKey="Thompson M" first="Mark G" last="Thompson">Mark G. Thompson</name></noRegion><name sortKey="Azziz Baumgartner, Eduardo" sort="Azziz Baumgartner, Eduardo" uniqKey="Azziz Baumgartner E" first="Eduardo" last="Azziz-Baumgartner">Eduardo Azziz-Baumgartner</name><name sortKey="Dawood, Fatimah S" sort="Dawood, Fatimah S" uniqKey="Dawood F" first="Fatimah S" last="Dawood">Fatimah S. Dawood</name></country><country name="Canada"><region name="Ontario"><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name></region><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name><name sortKey="Fell, Deshayne B" sort="Fell, Deshayne B" uniqKey="Fell D" first="Deshayne B" last="Fell">Deshayne B. Fell</name><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><name sortKey="Simmonds, Kimberley" sort="Simmonds, Kimberley" uniqKey="Simmonds K" first="Kimberley" last="Simmonds">Kimberley Simmonds</name><name sortKey="Simmonds, Kimberley" sort="Simmonds, Kimberley" uniqKey="Simmonds K" first="Kimberley" last="Simmonds">Kimberley Simmonds</name><name sortKey="Svenson, Lawrence W" sort="Svenson, Lawrence W" uniqKey="Svenson L" first="Lawrence W" last="Svenson">Lawrence W. Svenson</name><name sortKey="Svenson, Lawrence W" sort="Svenson, Lawrence W" uniqKey="Svenson L" first="Lawrence W" last="Svenson">Lawrence W. Svenson</name><name sortKey="Svenson, Lawrence W" sort="Svenson, Lawrence W" uniqKey="Svenson L" first="Lawrence W" last="Svenson">Lawrence W. Svenson</name></country><country name="Australie"><noRegion><name sortKey="Regan, Annette K" sort="Regan, Annette K" uniqKey="Regan A" first="Annette K" last="Regan">Annette K. Regan</name></noRegion><name sortKey="Effler, Paul V" sort="Effler, Paul V" uniqKey="Effler P" first="Paul V" last="Effler">Paul V. Effler</name><name sortKey="Levy, Avram" sort="Levy, Avram" uniqKey="Levy A" first="Avram" last="Levy">Avram Levy</name></country><country name="Israël"><noRegion><name sortKey="Katz, Mark A" sort="Katz, Mark A" uniqKey="Katz M" first="Mark A" last="Katz">Mark A. Katz</name></noRegion></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Wyant, Brandy E" sort="Wyant, Brandy E" uniqKey="Wyant B" first="Brandy E" last="Wyant">Brandy E. Wyant</name></region><name sortKey="Ball, Sarah W" sort="Ball, Sarah W" uniqKey="Ball S" first="Sarah W" last="Ball">Sarah W. Ball</name><name sortKey="Fink, Rebecca V" sort="Fink, Rebecca V" uniqKey="Fink R" first="Rebecca V" last="Fink">Rebecca V. Fink</name><name sortKey="Jackson, Michael L" sort="Jackson, Michael L" uniqKey="Jackson M" first="Michael L" last="Jackson">Michael L. Jackson</name><name sortKey="Naleway, Allison" sort="Naleway, Allison" uniqKey="Naleway A" first="Allison" last="Naleway">Allison Naleway</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000023 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000023 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30307490
|texte= Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30307490" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |